We are live on ! Find out more
JGUA

John G. Ullman & Associates Portfolio holdings

AUM $754M
1-Year Est. Return 60.05%
This Fund
S&P 500
This Quarter Est. Return
+3.93%
1 Year Est. Return
+60.05%
3 Year Est. Return
+108.28%
5 Year Est. Return
+118.76%
10 Year Est. Return
+308.24%
AUM
$548M
AUM Growth
+$7.66M
Cap. Flow
-$12M
Cap. Flow %
-2.19%
Top 10 Hldgs %
32.65%
Holding
154
New
7
Increased
23
Reduced
102
Closed
2

Top Sells

Rank Stock Value
1
EXC icon
Exelon
EXC
+$4.98M
2
STE icon
Steris
STE
+$4.1M
3
FCX icon
Freeport-McMoran
FCX
+$2.26M
4
ADI icon
Analog Devices
ADI
+$2.16M
5
JNJ icon
Johnson & Johnson
JNJ
+$1.91M

Sector Composition

Rank Sector Weight
1 Healthcare 24.56%
2 Industrials 19.03%
3 Technology 17.84%
4 Energy 9.49%
5 Utilities 7.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LNN icon
26
Lindsay Corp
LNN
$1.15B
$6.57M 1.2%
77,748
+1,430
+2% +$124K
NEE icon
27
NextEra Energy
NEE
$186B
$6.14M 1.12%
239,492
-6,408
-3% -$156K
DUK icon
28
Duke Energy
DUK
$98.7B
$5.88M 1.07%
79,251
-2,222
-3% -$160K
EWS icon
29
iShares MSCI Singapore ETF
EWS
$1.01B
$5.31M 0.97%
196,493
-1,625
-0.8% -$44.2K
POR icon
30
Portland General Electric
POR
$6.11B
$5.01M 0.91%
144,385
-2,400
-2% -$79.1K
SIAL
31
DELISTED
SIGMA - ALDRICH CORP
SIAL
$4.87M 0.89%
47,975
-2,450
-5% -$238K
MDT icon
32
Medtronic
MDT
$106B
$4.79M 0.87%
75,083
-2,006
-3% -$122K
MDU icon
33
MDU Resources
MDU
$4.42B
$4.76M 0.87%
356,875
-98,753
-22% -$1.29M
GE icon
34
GE Aerospace
GE
$367B
$4.67M 0.85%
37,057
-198
-0.5% -$25.2K
OVV icon
35
Ovintiv
OVV
$16.1B
$4.39M 0.8%
37,020
-3,470
-9% -$402K
TMO icon
36
Thermo Fisher Scientific
TMO
$197B
$4.37M 0.8%
37,050
-900
-2% -$106K
LLY icon
37
Eli Lilly
LLY
$1.05T
$4.34M 0.79%
69,788
-500
-0.7% -$29.8K
AMAT icon
38
Applied Materials
AMAT
$438B
$4.3M 0.79%
190,930
-2,900
-1% -$59.2K
OTTR icon
39
Otter Tail
OTTR
$3.92B
$4.16M 0.76%
137,378
+128,978
+1,535% +$3.75M
ADI icon
40
Analog Devices
ADI
$186B
$4.05M 0.74%
74,876
-40,890
-35% -$2.16M
TT icon
41
Trane Technologies
TT
$104B
$3.95M 0.72%
63,220
+20,070
+47% +$1.19M
TMP icon
42
Tompkins Financial
TMP
$1.35B
$3.73M 0.68%
77,350
-4,500
-5% -$213K
EEM icon
43
iShares MSCI Emerging Markets ETF
EEM
$28.4B
$3.69M 0.67%
85,400
+800
+0.9% +$34K
PG icon
44
Procter & Gamble
PG
$346B
$3.68M 0.67%
46,797
-600
-1% -$48.4K
AAPL icon
45
Apple
AAPL
$4.85T
$3.66M 0.67%
157,608
-172
-0.1% -$3.66K
FLS icon
46
Flowserve
FLS
$8.77B
$3.65M 0.67%
49,065
-2,670
-5% -$202K
ITRI icon
47
Itron
ITRI
$3.85B
$3.53M 0.65%
87,150
-2,250
-3% -$85.6K
XRAY icon
48
Dentsply Sirona
XRAY
$2.79B
$3.31M 0.6%
69,920
-3,350
-5% -$156K
DIS icon
49
Walt Disney
DIS
$167B
$3.29M 0.6%
38,377
-300
-0.8% -$24.5K
EMC
50
DELISTED
EMC CORPORATION
EMC
$3.23M 0.59%
122,720
+29,200
+31% +$771K

Similar funds

John G. Ullman & Associates's Q2 2014 Portfolio in Review

As of Q2 2014, John G. Ullman & Associates held 154 positions worth $548M, up 1.4% from $540M the previous quarter. Its ten largest holdings account for 33% of the portfolio.

John G. Ullman & Associates's Q2 2014 filing shows 7 new, 23 increased, 102 reduced and 2 closed positions. Its largest new stake was State Street SPDR S&P Biotech ETF: 47,646 shares worth $2.45M. The largest sale was Exelon, an estimated $4.98M.

By sector, the portfolio is most concentrated in Healthcare at 25% of assets, down from 25% a quarter earlier, followed by Industrials and Technology.

  • John G. Ullman & Associates's largest Q2 2014 buy was State Street SPDR S&P Biotech ETF: 47,646 shares worth $2.45M.
  • John G. Ullman & Associates added most to Otter Tail in Q2 2014, an estimated $3.75M increase.
  • John G. Ullman & Associates's biggest Q2 2014 reduction was Exelon, cutting an estimated $4.98M.
  • John G. Ullman & Associates fully exited Halliburton in Q2 2014, selling an estimated $707K.
  • John G. Ullman & Associates's ten largest holdings make up 33% of its $548M portfolio in Q2 2014.
  • John G. Ullman & Associates opened 7 new positions and closed 2 in Q2 2014.
  • John G. Ullman & Associates's portfolio value rose 1.4% quarter-over-quarter to $548M.

Based on John G. Ullman & Associates's 13F filing for Q2 2014, filed 18 Jul 2014.